AnPac Bio Announces Receipt of the First Payment from a Malaysia Customer On a Signed US$1.5 Million Cancer Detection Equipment Purchase Contract
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) announced it received a $1.5 million payment from a Malaysian customer for its Model AP9080 cancer detection devices, marking its entry into the Southeast Asia market. This sale represents a significant milestone, confirming the Company's Cancer Differentiation Analysis Technology (CDA). The contract includes maintenance services and consumables, providing ongoing revenue. With a strong reputation in multi-cancer testing, AnPac Bio aims to capitalize on growth opportunities in Asia, driven by its patented technology known for high sensitivity and cost-effectiveness.
- First payment received of US$1.5 million from a Malaysian customer.
- Entry into the Southeast Asia market for cancer detection equipment.
- Ongoing revenue potential from maintenance services and consumables.
- AnPac Bio's CDA technology recognized for its effectiveness and cost efficiency.
- None.
Under the terms of the purchase contract, AnPac Bio will provide its Model AP9080 cancer detection device, maintenance services, consumables and equipment parts to the Malaysian customer. The Company will continue to receive revenues from services, consumables and equipment parts after the equipment sale. The Malaysian customer plans to set up bio-medical labs, obtain Laboratory Developed Test (LDT) certification and carry out paid cancer tests.
The Company's CDA cancer detection technology is based on measuring biophysical properties in the blood. It has several major advantages over the traditional technologies, including its ability to detect multiple cancer types at early stage, while being cost effective, relatively simple to implement, and provides high sensitivity and specificity. According to a report by US marketing research firm
Dr.
About AnPac Bio
For more information, please visit: https://www.Anpacbio.com.
For investor and media inquiries, please contact:
Ascent Investor Relations LLC
Phone: +1-917-609-0333 (US)
Email: tina.xiao@ascent-ir.com
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "target," "aim," "predict," "outlook," "seek," "goal" "objective," "assume," "contemplate," "continue," "positioned," "forecast," "likely," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to comply with Nasdaq Listing Rules, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant
SOURCE
FAQ
What is the significance of AnPac Bio's $1.5 million contract?
How does AnPac Bio's technology compare to traditional cancer detection methods?
What are the future prospects for AnPac Bio in Asia?
When did AnPac Bio receive the payment from Malaysia?